Today: 19 July 2026
Browse Category

NASDAQ:BIIB 25 August 2025 - 21 May 2026

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares slipped 1.2% to $35.80 in early premarket moves Tuesday, following a 5.7% jump to $36.23 at Monday’s close. Wolfe Research kicked off its coverage with an “Outperform” and tagged a $40 price target. The stock remains below its 52-week peak of $38.69, while roughly 21.6% of the float is sold short, according to MarketBeat.
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen Inc. is in focus on Monday, December 22, 2025—a day that combines company-specific clinical headlines with a major index event for the stock. Investors are weighing fresh long‑term data for QALSODY in a rare genetic form of ALS, Biogen’s public statement honoring co‑founder Charles Weissmann, and the market mechanics of Biogen’s removal from the Nasdaq‑100, which becomes effective today.
22 December 2025
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Inc. heads into the Christmas week with its stock hovering just below a recent high, a fresh spike in trading volume, and a narrative that’s increasingly dominated by one question: can the company turn Leqembi’s momentum into a durable growth engine while legacy revenue lines mature and competition intensifies?
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Inc. is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapiests2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B estng.investing.com – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS of $14.50–$15.00, citing an anticipated ~$1.25 per-share charge in Q4 for recent R&D dealsreuters.comreuters.com.
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

AI Designs New Viruses: In a stunning demonstration of AI’s creative power, scientists announced they have used artificial intelligence to design the first-ever viruses from scratch. The AI wrote complete viral genomes for bacteriophages which were then synthesized in the lab nature.com. Several of these AI-generated phages successfully infected and killed E. coli bacteria that natural phages couldn’t attack nature.com. “This is the first time AI systems are able to write coherent genome-scale sequences,” said Stanford computational biologist Brian Hie, calling it a step toward “AI-generated life” nature.com. While still in preprint and not yet peer-reviewed, the breakthrough suggests AI could become a powerful tool for engineering new biomedical therapies nature.com nature.com. Researchers hope AI-designed phages might one day help fight antibiotic-resistant superbugs nature.com nature.com – showcasing a real-world payoff for AI in medicine. The work also raises biosafety questions, as wholly novel organisms can now be created digitally, underscoring the need for oversight as “the next step is AI-generated life,” in Hie’s words nature.com.
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

This comprehensive roundup highlights the fast-moving developments in biotech, pharma, and health over the past 48 hours. From life-saving drugs and high-stakes deals to public health challenges, the landscape is evolving daily. As always, readers are advised to consult original sources and official health guidance for more details.
Go toTop